Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

retrospective cohort study based on electronic medical records data to compare the incidence of ORC in adults (≥24 years) living with obesity and diabetes who were treated with a first-generation ...

The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...

GLP-1 Receptor Agonist Market Demand 2025 BURLINGAME ... images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN ...

In clinical trials, semaglutide proved to be superior to placebo, with weight loss reaching 15%, suggesting its superiority over other non-GLP-1 RA anti ... undertreated in comparison to its ...

A systematic review and meta-analysis published in JAMA Psychiatry found little evidence of increased suicidality among glucagon-like peptide 1 receptor agonist (GLP-1 RA) recipients in ... as ...

Among adults with diabetes or obesity, the rate of suicide is unlikely to increase with the use of GLP-1 RAs. A systematic review and meta-analysis published in JAMA Psychiatry found little ...

Asked how this intervention might compare with drugs in development to mitigate muscle loss with GLP-1 RA therapy, Peralta-Reich said “while we are optimistic we are not applying the results of ...

Participants in the latest funding round for Woburn, Massachusetts-based Vaxess included RA Capital Management ... how the properties compare to the typical method of subcutaneous injection in a swine ...